Studies show increased risk of blood clots when taking oral contraception with drospirenone

(PhysOrg.com) -- Two new drug safety studies conducted by researchers at Boston University School of Medicine (BUSM) provide strong evidence that women taking oral contraception with drospirenone have an increased risk of nonfatal venous thromboembolism, or blood clots, compared to women taking oral contraception with levonorgestrel.

The two studies were led by Susan S. Jick, D.Sc., director of the Boston Collaborative Drug Surveillance Program at BUSM and professor of Epidemiology at Boston University School of Public Health. The results are published in the .

A number of studies examining the risk of nonfatal in women taking containing drospirenone have recently been published, but, according to Jick, have had limitations. The previous studies did not take into account women who had additional risk factors for blood clots, including a recent surgery, pregnancy or lower limb injury. Additionally, some of the other studies did not take into account previous instances of blood clots.

"When doing research to understand drug safety, certain methods need to be used, and our study addressed the limitations of the others," said Jick.

Jick and her colleagues conducted the two studies simultaneously using two different data resources - one from the United Kingdom and the other from the United States. In both studies, participants were women between the ages of 15 and 44 who had received drospirenone-containing or levonorgestrel-containing oral contraception and had not experienced a blood clot before, nor did they have additional risk factors.

The UK study found that women taking drospirenone contraception had a three-fold higher risk of non-fatal blood clots compared with women taking levonorgestrel contraception. In the study examining women in the US, women taking drospirenone contraception had double the risk of non-fatal blood clots compared with women taking levonorgestrel contraception.

"Our data clearly shows an increased risk in women taking drospirenone contraceptives compared to contraceptives," said Jick. "It is important for women to be informed about the risks and benefits of the different oral contraceptives so they can make informed decisions."

Provided by Boston University School of Medicine

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New warning OK'd for birth control patch

Jan 21, 2008

The U.S. Food and Drug Administration has approved a warning for the Ortho Evra Contraceptive Transdermal Patch label concerning the risk of blood clots.

FDA panel to consider new 'morning-after pill'

Jun 08, 2010

A Food and Drug Administration advisory committee will meet June 17 to consider whether the agency should approve a new emergency contraceptive that studies show is more effective than Plan B, the only "morning-after pill" ...

'Morning After Pill' Works up to 5 Days After Sex

Feb 22, 2010

(PhysOrg.com) -- A team of researchers from the United States and Europe has published new evidence supporting the use of ulipristal acetate as an effective alternative to levonorgestrel (marketed as Plan B®) for emergency ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments